Stahl M - Search Results

1

Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.

Shimony S, Bewersdorf JP, Shallis RM, Liu Y, Schaefer EJ, Zeidan AM, Goldberg AD, Stein EM, Marcucci G, Lindsley RC, Chen EC, Ramos Perez J, Stein A, DeAngelo DJ, Neuberg DS, Stone RM, Ball B, Stahl M. Shimony S, et al. Among authors: stahl m. Leukemia. 2024 Apr;38(4):762-768. doi: 10.1038/s41375-024-02175-0. Epub 2024 Feb 20. Leukemia. 2024. PMID: 38378841

2

Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.

Stahl M, Xu ML, Steensma DP, Rampal R, Much M, Zeidan AM. Stahl M, et al. Ann Hematol. 2016 Jun;95(7):1197-200. doi: 10.1007/s00277-016-2664-4. Epub 2016 Apr 11. Ann Hematol. 2016. PMID: 27068405 Free PMC article. No abstract available.

3

Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia.

Kim TK, Xu ML, Podoltsev NA, Prebet T, Barbarotta L, Amin K, Kasberg S, Roche K, Stahl M, Gore SD, Zeidan AM. Kim TK, et al. Among authors: stahl m. Ann Hematol. 2016 Oct;95(11):1895-8. doi: 10.1007/s00277-016-2761-4. Epub 2016 Jul 29. Ann Hematol. 2016. PMID: 27468851 Free PMC article. No abstract available.

4

Emerging biological therapies for the treatment of myelodysplastic syndromes.

Zeidan AM, Stahl M, Komrokji R. Zeidan AM, et al. Among authors: stahl m. Expert Opin Emerg Drugs. 2016 Sep;21(3):283-300. doi: 10.1080/14728214.2016.1220534. Epub 2016 Aug 19. Expert Opin Emerg Drugs. 2016. PMID: 27486848 Review.

5

Epigenetics in Cancer: A Hematological Perspective.

Stahl M, Kohrman N, Gore SD, Kim TK, Zeidan AM, Prebet T. Stahl M, et al. PLoS Genet. 2016 Oct 10;12(10):e1006193. doi: 10.1371/journal.pgen.1006193. eCollection 2016 Oct. PLoS Genet. 2016. PMID: 27723796 Free PMC article. Review.

6

Selecting initial treatment of acute myeloid leukaemia in older adults.

Podoltsev NA, Stahl M, Zeidan AM, Gore SD. Podoltsev NA, et al. Among authors: stahl m. Blood Rev. 2017 Mar;31(2):43-62. doi: 10.1016/j.blre.2016.09.005. Epub 2016 Oct 8. Blood Rev. 2017. PMID: 27745715 Review.

7

Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities.

Stahl M, Kim TK, Zeidan AM. Stahl M, et al. World J Stem Cells. 2016 Oct 26;8(10):316-331. doi: 10.4252/wjsc.v8.i10.316. World J Stem Cells. 2016. PMID: 27822339 Free PMC article. Review.

8

Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel?

Stahl M, Zeidan AM. Stahl M, et al. Cancer. 2017 May 15;123(6):911-914. doi: 10.1002/cncr.30532. Epub 2017 Jan 17. Cancer. 2017. PMID: 28094843 Free article. No abstract available.

9

Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.

Stahl M, Zeidan AM. Stahl M, et al. Cancer. 2017 May 15;123(10):1703-1713. doi: 10.1002/cncr.30585. Epub 2017 Feb 13. Cancer. 2017. PMID: 28192601 Free article. Review.

10

Reactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced myelodysplastic syndrome.

Weed J, Ko C, Stahl M, Much M, Witt D, Zeidan AM, Leventhal J. Weed J, et al. Among authors: stahl m. Ann Hematol. 2017 Jun;96(6):1037-1039. doi: 10.1007/s00277-017-2954-5. Epub 2017 Feb 20. Ann Hematol. 2017. PMID: 28220192 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,126 results

Search Page